Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Abstract
Purpose of review Obesity is a global health crisis with detrimental effects on all organ systems leading to worsening disease state and rising costs of care. Persons with obesity failing lifestyle therapies need to be escalated to appropriate pharmacological treatment modalities, medical devices, and/or bariatric surgery if criteria are met and more aggressive intervention is needed. The progression of severe obesity in the patient population coupled with related co-morbidities necessitates the development of novel therapies for the treatment of obesity. This development is preceded by increased understanding of the underpinnings of energy regulation and neurohormonal pathways involved in energy homeostasis. Recent findings Though there are approved anti-obesity drugs available in the USA, newer drugs are now in the pipeline for development given the urgent need. This review focuses on anti-obesity drugs in the pipeline including centrally acting agents (setmelanotide, neuropeptide Y antagonist [velneperit], zonisamide-bupropion [Empatic], cannabinoid type-1 receptor blockers), gut hormones and incretin targets (new glucagon-like-peptide-1 [GLP-1] analogues [semaglutide and oral equivalents], amylin mimetics [davalintide, dual amylin and calcitonin receptor agonists], dual action GLP-1/glucagon receptor agonists [oxyntomodulin], triple agonists [tri-agonist 1706], peptide YY, leptin analogues [combination pramlintide-metreleptin]), and other novel targets (methionine aminope…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a nod to this idea, current antiobesity medications in the pipeline include dual agonist and triple agonist agents, drugs that simultaneously target multiple pathways (eg, tirzepatide, which targets GLP-1 receptor agonist and GIP receptor agonist) 43 in an attempt to circumvent these natural redundancies.149 -152”
From Effectiveness and safety of drugs for obesity (2024) · cites this paper as [149]
In the citing paper
“Some, but not all, GLP-1 RAs have clinical trial evidence supporting favorable effects on cardiovascular disease (CVD) outcomes [122,[140], [141], [142], [143], [144], [145], [146], [147]].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [140]
In the citing paper
“Leptin, produced by adipocytes, was initially considered a potential target for development in anti-obesity medication as early animal studies showed the linkage between leptin deficiency and severe obesity [11].”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [11]
In the citing paper
“Data from the most recent meta-analyses showed that the overall placebo-subtracted weight reduction (%) with the use of anti-obesity drugs for at least 12 months ranged from 2.9 to 6.8%: phentermine/topiramate (3 trials, 6.8%) liraglutide (4 trials, 5.4%), naltrexone/bupropion (5 trials, 4.0%), and orlistat (17 trials, 2.9%) [11, 54, 81–84] (Table 2).”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [11]
Citations
Cites
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Peptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,030
Trends in Obesity Among Adults in the United States, 2005 to 2014
Flegal, K. M., Kruszon-Moran, D., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2016) · JAMA · doi:10.1001/jama.2016.6458 · Cited by 2,803
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
Kovesdy, C. P., Furth, S. L., Zoccali, C., & on behalf of the World Kidney Day Steering Committee (2017) · American Journal of Nephrology · doi:10.1159/000458467 · Cited by 2,217
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
The cloning of a family of genes that encode the melanocortin receptors
Mountjoy, K. G., Robbins, L. S., Mortrud, M. T., & Cone, R. D. (1992) · Science · doi:10.1126/science.1325670 · Cited by 1,635
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Anatomy and regulation of the central melanocortin system
Cone, R. D. (2005) · Nature Neuroscience · doi:10.1038/nn1455 · Cited by 1,583
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Self-citationDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963
Understanding the Physiology of FGF21
Fisher, F. M., & Maratos-Flier, E. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105339 · Cited by 912
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Glucagon and regulation of glucose metabolism
Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S., & Maratos-Flier, E. (2010) · Diabetes · doi:10.2337/db10-0193 · Cited by 830
Gut hormones and the regulation of energy homeostasis
Murphy, K. G., & Bloom, S. R. (2006) · Nature · doi:10.1038/nature05484 · Cited by 778
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Elliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., & Marks, V. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1380159 · Cited by 695
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Studies on the Physiological Functions of the Melanocortin System
Cone, R. D. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0034 · Cited by 615
Anti-Obesity Drugs: A Review about Their Effects and Safety
Kang, J. G., & Park, C.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.1.13 · Cited by 593
Understanding and Addressing the Epidemic of Obesity: An Energy Balance Perspective
Hill, J. O. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0032 · Cited by 589
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Rossi, M., Kim, M. S., Morgan, D. G. A., Small, C. J., Edwards, C. M. B., Sunter, D., Abusnana, S., Goldstone, A. P., Russell, S. H., Stanley, S. A., et al. (1998) · Endocrinology · doi:10.1210/endo.139.10.6332 · Cited by 576
Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 561
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495
Appetite suppression and weight loss after the cannabinoid antagonist SR 141716
Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R., & Gessa, G. L. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00322-1 · Cited by 487
Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist
Kühnen, P., Clément, K., Wiegand, S., Blankenstein, O., Gottesdiener, K., Martini, L. L., Mai, K., Blume-Peytavi, U., Grüters, A., & Krude, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512693 · Cited by 485
Modulation of Blood Pressure by Central Melanocortinergic Pathways
Greenfield, J. R., Miller, J. W., Keogh, J. M., Henning, E., Satterwhite, J. H., Cameron, G. S., Astruc, B., Mayer, J. P., Brage, S., See, T. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0803085 · Cited by 477
Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans
Cohen, M. A., Ellis, S. M., Le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030421 · Cited by 472
Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
Current pharmacotherapy for obesity
Srivastava, G., & Apovian, C. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.122 · Cited by 397
Self-citationFibroblast Growth Factor 21-Deficient Mice Demonstrate Impaired Adaptation to Ketosis
Badman, M. K., Koester, A., Flier, J. S., Kharitonenkov, A., & Maratos-Flier, E. (2009) · Endocrinology · doi:10.1210/en.2009-0532 · Cited by 362
Glucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
Global Health Effects of Overweight and Obesity
Gregg, E. W., & Shaw, J. E. (2017) · New England Journal of Medicine · doi:10.1056/nejme1706095 · Cited by 341
Ravussin, E., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E., & Weyer, C. (2009) · Obesity · doi:10.1038/oby.2009.184 · Cited by 332
GLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290
20 YEARS OF LEPTIN: Human disorders of leptin action
Farooqi, I. S., & O'Rahilly, S. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0480 · Cited by 280
Aronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S., & Gadde, K. M. (2013) · Obesity · doi:10.1002/oby.20584 · Cited by 274
Guide to Receptors and Channels (GRAC), 4th edition
(2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00499.x · Cited by 249
Monami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243
Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240
Functional GIP Receptors Are Present on Adipocytes
Yip, R. G.-C., Boylan, M. O., Kieffer, T. J., & Wolfe, M. M. (1998) · Endocrinology · doi:10.1210/endo.139.9.6288 · Cited by 237
Kievit, P., Halem, H., Marks, D. L., Dong, J. Z., Glavas, M. M., Sinnayah, P., Pranger, L., Cowley, M. A., Grove, K. L., & Culler, M. D. (2013) · Diabetes · doi:10.2337/db12-0598 · Cited by 231
Vickers, S. P., Webster, L. J., Wyatt, A., Dourish, C. T., & Kennett, G. A. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1384-8 · Cited by 207
Astrup, A., Madsbad, S., Breum, L., Jensen, T. J., Kroustrup, J. P., & Larsen, T. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61525-1 · Cited by 193
Cluny, N., Vemuri, V., Chambers, A., Limebeer, C., Bedard, H., Wood, J., Lutz, B., Zimmer, A., Parker, L., Makriyannis, A., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00908.x · Cited by 193
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
Hildebrandt, A. L., Kelly-Sullivan, D. M., & Black, S. C. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01343-8 · Cited by 181
High protein intake stimulates postprandial GLP1 and PYY release
van der Klaauw, A. A., Keogh, J. M., Henning, E., Trowse, V. M., Dhillo, W. S., Ghatei, M. A., & Farooqi, I. S. (2013) · Obesity · doi:10.1002/oby.20154 · Cited by 175
Chen, K. Y., Muniyappa, R., Abel, B. S., Mullins, K. P., Staker, P., Brychta, R. J., Zhao, X., Ring, M., Psota, T. L., Cone, R. D., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4024 · Cited by 174
Effect of Glucagon on Food Intake and Body Weight in Man
Schulman, J. L., Carleton, J. L., Whitney, G., & Whitehorn, J. C. (1957) · Journal of Applied Physiology · doi:10.1152/jappl.1957.11.3.419 · Cited by 174
Fibroblast growth factor-21, energy balance and obesity
Giralt, M., Gavaldà‐Navarro, A., & Villarroya, F. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.018 · Cited by 161
New Drug Targets for the Treatment of Obesity
Powell, A. G., Apovian, C. M., & Aronne, L. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.82 · Cited by 161
Self-citationFibroblast growth factor 21 and its novel association with oxidative stress
Gómez-Sámano, M. Á., Grajales-Gómez, M., Zuarth-Vázquez, J. M., Navarro-Flores, M. F., Martínez-Saavedra, M., Juárez-León, Ó. A., Morales-García, M. G., Enríquez-Estrada, V. M., Gómez-Pérez, F. J., & Cuevas-Ramos, D. (2017) · Redox Biology · doi:10.1016/j.redox.2016.12.024 · Cited by 161
Kopelman, P., Bryson, A. L., Hickling, R. I., Rissanen, A., Rössner, S., Toubro, S., & Valensi, P. E. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803446 · Cited by 156
Clinical Effects of Long-Term Metreleptin Treatment in Patients With Lipodystrophy
Chan, J. L., Lutz, K., Cochran, E. K., Huang, W., Peters, Y., Weyer, C., & Görden, P. (2011) · Endocrine Practice · doi:10.4158/ep11229.or · Cited by 156
Weight regain after Roux-en-Y: A significant 20% complication related to PYY
Meguid, M. M., Glade, M. J., & Middleton, F. A. (2008) · Nutrition · doi:10.1016/j.nut.2008.06.027 · Cited by 153
Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study
Gaal, L. F. V., Broom, J. I., Enzi, G., & Toplak, H. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050433 · Cited by 149
60 YEARS OF POMC: Regulation of feeding and energy homeostasis by α-MSH
Anderson, E. J. P., Çakir, I., Carrington, S. J., Cone, R. D., Ghamari-Langroudi, M., Gillyard, T., Gimenez, L. E., & Litt, M. J. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0014 · Cited by 146
Salamone, J. D., McLaughlin, P. J., Sink, K. S., Makriyannis, A., & Parker, L. A. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.04.013 · Cited by 130
Neural melanocortin receptors in obesity and related metabolic disorders
Girardet, C., & Butler, A. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.004 · Cited by 128
Seino, Y., Terauchi, Y., Osonoi, T., Yabe, D., Abe, N., Nishida, T., Zacho, J., & Kaneko, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13082 · Cited by 127
Knapper, J. M. E., Puddicombe, S. M., Morgan, L., & Fletcher, J. M. (1995) · Journal of Nutrition · doi:10.1093/jn/125.2.183 · Cited by 126
The future role of gut hormones in the treatment of obesity
Troke, R. C., Tan, T. M., & Bloom, S. R. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313506730 · Cited by 125
Pancreatic Amylin as a Centrally Acting Satiating Hormone
Lutz, T. A. (2005) · Current Drug Targets · doi:10.2174/1389450053174596 · Cited by 122
Fani, L., Bak, S., Delhanty, P., van Rossum, E. F. C., & van den Akker, E. L. T. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.80 · Cited by 121
Takagi, K., Legrand, R., Asakawa, A., Amitani, H., François, M., Tennoune, N., Coëffier, M., Claeyssens, S., do Rego, J.-C., Déchelotte, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3685 · Cited by 121
A one-year trial to assess the value of orlistat in the management of obesity.
James, W. P. T., Avenell, A., Broom, J. I., & Whitehead, J. (1997) · PubMed · Cited by 118
Mack, C. M., Soares, C. J., Wilson, J., Athanacio, J., Turek, V. F., Trevaskis, J. L., Roth, J. D., Smith, P. A., Gedulin, B. R., Jodka, C. M., et al. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.238 · Cited by 118
Nørregaard, P. K., Deryabina, M. A., Tofteng Shelton, P., Fog, J. U., Daugaard, J. R., Eriksson, P., Larsen, L. F., & Jessen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13034 · Cited by 116
Parker, J. A., McCullough, K. A., Field, B. C. T., Minnion, J. S., Martin, N. M., Ghatei, M. A., & Bloom, S. R. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.227 · Cited by 111
Bailey, R., Walker, C., Ferner, A., Loomes, K., Prijic, G., Halim, A., Whiting, L., Phillips, A., & Hay, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01717.x · Cited by 101
Tolle, V., & Low, M. J. (2008) · Diabetes · doi:10.2337/db07-0733 · Cited by 100
Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis
Domouzoglou, E. M., & Maratos–Flier, E. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.001941 · Cited by 100
Metreleptin: First Global Approval
Chou, K., & Perry, C. M. (2013) · Drugs · doi:10.1007/s40265-013-0074-7 · Cited by 99
Depression and anxiety with rimonabant
Mitchell, P. B., & Morris, M. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61705-x · Cited by 95
Kumar, K. G., Sutton, G. M., Dong, J. Z., Roubert, P., Plas, P., Halem, H. A., Culler, M. D., Yang, H., Dixit, V. D., & Butler, A. A. (2009) · Peptides · doi:10.1016/j.peptides.2009.07.012 · Cited by 93
Kopelman, P., de Groot, H. G., Rissanen, A., Rossner, S., Toubro, S., Palmer, R., Hallam, R., Bryson, A., & Hickling, R. I. (2010) · Obesity · doi:10.1038/oby.2009.155 · Cited by 93
Gadde, K. M., Yonish, G. M., Foust, M. S., & Wagner, H. R. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0809 · Cited by 84
New and Emerging Drug Molecules Against Obesity
George, M., Rajaram, M., & Shanmugam, E. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413501017 · Cited by 77
Singh‐Franco, D., Perez, A., & Harrington, C. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01337.x · Cited by 76
Meehan, C. A., Cochran, E., Kassai, A., Brown, R. J., & Gorden, P. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1096772 · Cited by 73
Long-term weight control study II (weeks 34 to 104)
Weintraub, M., Sundaresan, P. R., Schuster, B., Ginsberg, G., Madan, M., Balder, A., Stein, E. C., & Byrne, L. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.70 · Cited by 72
Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy
Chan, J. L., Koda, J., Heilig, J. S., Cochran, E. K., Gorden, P., Oral, E. A., & Brown, R. J. (2016) · Clinical Endocrinology · doi:10.1111/cen.12980 · Cited by 72
The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior
Randall, P. A., Vemuri, V. K., Segovia, K. N., Torres, E. F., Hosmer, S., Nunes, E. J., Santerre, J. L., Makriyannis, A., & Salamone, J. D. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.021 · Cited by 70
Hughes, T. E., Kim, D. D., Marjason, J., Proietto, J., Whitehead, J. P., & Vath, J. E. (2013) · Obesity · doi:10.1002/oby.20356 · Cited by 66
Krakoff, J., Ma, L., Kobes, S., Knowler, W. C., Hanson, R. L., Bogardus, C., & Baier, L. J. (2008) · Diabetes · doi:10.2337/db08-0577 · Cited by 66
Gut hormones as pharmaceuticals
Holst, J. J. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00185-3 · Cited by 65
Effects of Metreleptin in Pediatric Patients With Lipodystrophy
Brown, R. J., Meehan, C. A., Cochran, E., Rother, K. I., Kleiner, D. E., Walter, M., & Gorden, P. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3628 · Cited by 65
Safety and Efficacy of Lorcaserin: A Combined Analysis of the BLOOM and BLOSSOM Trials
Aronne, L., Shanahan, W., Fain, R., Glicklich, A., Soliman, W., Li, Y., & Smith, S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.10.2817 · Cited by 64
Chun, E., Han, C. K., Yoon, J. H., Sim, T. B., Kim, Y., & Lee, K. (2004) · International Journal of Cancer · doi:10.1002/ijc.20687 · Cited by 62
Obesity pharmacotherapy: What is next?
Colon-Gonzalez, F., Kim, G. W., Lin, J. E., Valentino, M. A., & Waldman, S. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.005 · Cited by 62
Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial
Kim, D. D., Krishnarajah, J., Lillioja, S., de Looze, F., Marjason, J., Proietto, J., Shakib, S., Stuckey, B. G. A., Vath, J. E., & Hughes, T. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12457 · Cited by 62
Yamada, Y., Kato, T., OGINO, H., Ashina, S., & Kato, K. (2008) · Hormone and Metabolic Research · doi:10.1055/s-2008-1076699 · Cited by 61
Yamada, T., Hara, K., & Kadowaki, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042031 · Cited by 60
Gydesen, S., Andreassen, K. V., Hjuler, S. T., Christensen, J. M., Karsdal, M. A., & Henriksen, K. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00514.2015 · Cited by 57
Control of food intake and energy expenditure by amylin—therapeutic implications
Lutz, T. A. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.13 · Cited by 54
Mack, C. M., Smith, P. A., Athanacio, J. R., Xu, K., Wilson, J. K., Reynolds, J. M., Jodka, C. M., Lu, M. G. W., & Parkes, D. G. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01465.x · Cited by 49
J�rbe, T. U. C., & DiPatrizio, N. V. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00009 · Cited by 47
Naltrexone/bupropion for the Treatment of Obesity and Obesity With Type 2 Diabetes
Apovian, C. M. (2016) · Future Cardiology · doi:10.2217/fca.15.79 · Cited by 47
Self-citationChan, J. L., Roth, J. D., & Weyer, C. (2009) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3181b91911 · Cited by 44
Hjuler, S. T., Gydesen, S., Andreassen, K. V., Pedersen, S. L. K., Hellgren, L. I., Karsdal, M. A., & Henriksen, K. (2016) · Obesity · doi:10.1002/oby.21563 · Cited by 44
Hjuler, S. T., Andreassen, K. V., Gydesen, S., Karsdal, M. A., & Henriksen, K. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.051 · Cited by 41
Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., Aronne, L., & on behalf of the NN8022-1923 Investigators (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.88 · Cited by 40
A talk between fat tissue, gut, pancreas and brain to control body weight
Wilson, J. L., & Enriori, P. J. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.08.022 · Cited by 39
Hansen, M. S., Tencerová, M., Frølich, J. S., Kassem, M. S., & Frost, M. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12850 · Cited by 39
Modulation of energy balance by fibroblast growth factor 21
Ramos, D. C., & Aguilar-Salinas, C. A. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0023 · Cited by 38
Paschetta, E., Hvalryg, M., & Musso, G. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00897.x · Cited by 37
Translational studies on PYY as a novel target in obesity
Zac‐Varghese, S., Silva, A. D., & Bloom, S. R. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.10.001 · Cited by 37
Hansen, H. H., Jensen, M. M., Overgaard, A., Weikop, P., & Mikkelsen, J. D. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.07.018 · Cited by 36
Anti-ghrelin antibodies in appetite suppression: Recent advances in obesity pharmacotherapy
Rotkvic, V., & Altabas, V. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s60398 · Cited by 32
Na, H.-N., & Jh, N. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.41 · Cited by 29
Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man
Boess, F., Bertinetti-Lapatki, C., Zoffmann, S., George, C., Pfister, T., Roth, A., Lee, S. M. L., Thasler, W. E., Singer, T., & Suter, L. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0186 · Cited by 29
Hjuler, S. T., Gydesen, S., Andreassen, K. V., Karsdal, M. A., & Henriksen, K. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.241281 · Cited by 29
Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives
Tchang, B. G., Shukla, A. P., & Aronne, L. J. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1052789 · Cited by 28
Kim, E., & Shin, W.-H. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.217 · Cited by 25
Aspergillus , Angiogenesis, and Obesity: The Story Behind Beloranib
Howland, R. H. (2015) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20150219-01 · Cited by 24
Effects of novel vaccines on weight loss in diet-induced-obese (DIO) mice
Haffer, K. N. (2012) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/2049-1891-3-21 · Cited by 23
Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk
Wharton, S., & Serodio, K. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0590-z · Cited by 19
[Cellular localization, half-life, and secretion of peptide YY].
Lluı́s, F., Fujimura, M., Gómez, G., Salvá, J. A., Greeley, G. H., & Thompson, J. C. (1989) · PubMed · Cited by 18
Prophylactic and therapeutic vaccines for obesity
Na, H.-N., Kim, H., & Nam, J.-H. (2014) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2014.3.1.37 · Cited by 16
Monteiro, M. P. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27537 · Cited by 16
Tesofensine – a novel potent weight loss medicine
Doggrell, S. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902967632 · Cited by 15
Elfers, C. T., & Roth, C. L. (2017) · Endocrinology · doi:10.1210/en.2016-1665 · Cited by 15
New hormone treatment for obesity caused by POMC-deficiency
Low, M. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.156 · Cited by 8
A potent and selective neuropeptide Y Y5—receptor antagonist, S-2367, as an anti-obesity agent
Yukioka, H. (2010) · Folia Pharmacologica Japonica · doi:10.1254/fpj.136.270 · Cited by 7
Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy
Akıncı, G., & Akıncı, B. (2015) · Recent Patents on Endocrine Metabolic & Immune Drug Discovery · doi:10.2174/1574892811666151111142554 · Cited by 7
Research works printed but not linked: 6
- European Medicines Agency: European Public Assessment Report (EPAR) Acomplia. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000666/WC500021282.pdf Accessed September 27, 2017 (2007).
- R&D Pipeline. https://www.novonordisk.com/rnd/rd-pipeline.html Novo Nordisk Accessed August 28, 2017 (2017).
- Myalept [package insert]. Amylin Pharmaceuticals https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s000lbl.pdf Acccessed September 5, 2017 (2014).
- The Boston Globe: Zafgen drug halted after second patient dies. https://www.bostonglobe.com/business/2015/12/03/fda-orders-zafgen-halt-clinical-trial-for-obesity-drug/PwGxnqvLoIYpXZN59hPT6M/story.html Accessed September 27, 2017 (2015).
- Rhythm Pharmaceuticals, Inc Product pipeline: peptide therapeutics for rare genetic deficiencies resulting in life-threatening metabolic disorders. http://www.rhythmtx.com/pipeline/product-pipeline/ Accessed August 28, 2017 (2017).
- Double-blind, multi-center, randomized study to assess the efficacy and safety of velneperit (S-2367) and orlistat administered individually or combined with a reduced calorie diet (RCD) in obese subjects. https://clinicaltrials.gov/ct2/show/NCT01126970 Accessed September 13, 2017 (2011).
Cited by
Blüher, M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa004 · Cited by 1,090
“Adapted from references (102, 103); data on mean percentage of weight loss are from reference (102).”
BackgroundMethodAnti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Heymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Metadata
- Authors
- Srivastava, G., & Apovian, C.
- Affiliations
- Boston University (US)
- Corresponding author
- Apovian, Caroline
- Venue
- Current Obesity Reports
- Published
- 2018-03-05
- Volume
- 7
- Issue
- 2
- Pages
- 147-161
- ISSN
- 2162-4968 (ISSN-L)
- OpenAlex
- W2791667241
- Semantic Scholar
- 71b64a26019d6d43435b8399a756c7980dd9eeb9
- Cited by
- 232
- References
- 132
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 21 · 2023: 25 · 2022: 26 · 2021: 57 · 2020: 34 · 2019: 30 · 2018: 14
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Obesity Reports (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Shionogi
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity pharmacotherapy, anti-obesity drugs, drug development pipeline, setmelanotide, GLP-1 receptor agonists, semaglutide, amylin receptor agonist, oxyntomodulin, peptide YY, lipase inhibitors, FGF21, energy homeostasis, neurohormonal pathways
- MeSH terms
- Obesity Management, Animals, Humans, Obesity, Morbid, Weight Loss, Drugs, Investigational, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.